Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Renovo, Fusion IP and BioNeutral confirmed for 20 January Investor Forum

We have another cracking line-up prepared for Wednesday, January 20 2009 as we return to the biotech, intellectual property and pharmaceutical sectors at our next One2One Investor Forums in Mayfair, London.


All three companies, Fusion IP (AIM: FIP), BioNeutral Group (OTCBB: BONU) and Renovo Group Plc (LSE: RNVO) are expecting a busy year, as they develop their respective businesses, so there will be plenty for attendees to hear about.

Our investor forums are completely free to attend – to register simply Click Here

The forum will be hosted at the Chesterfield Mayfair Hotel, and will commence at 6pm, final entry is 6:30pm. The three companies have approximately 30 minutes to give a short presentation and for Q&A before a further 90 minutes of networking.

A short description on each of the presenting companies is below, and we look forward to seeing you on Wednesday.


Fusion IP (AIM: FIP)
owns the rights to 100% of the university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to invest in some the world's most advanced and exciting science, turning world class research into business through the creation of a growing portfolio of companies, in fields as varied as drug discovery, alternative energy and engineering.

BioNeutral Group (OTCBB:
BONU) is a specialty life science company commercializing a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. The formulations are green and include natural and common ingredients which are found in baby products and in the foods we eat.

Renovo Group (LSE:RNVO)
is a biopharmaceutical product company and is a leader in the discovery and development of drugs to improve the appearance of scars. Renovo aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Renovo's pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.

Ivestors interested in the following companies will also find the event highly beneficial

Abcam (AIM: ABC) produces and distributes research-grade antibodies via an online catalogue featuring detailed technical data sheets on each product. Abcam is headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japan office located in Tokyo.  Abcam is in the general retailers sector and is currently trading at 915.00p per share. In the last year Abcam's share price has ranged from 460.00p to 959.00p and brokers are currently rating this stock as 'buy'.

Angel Biotechnology (AIM: ABH)
principal activity is in the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. Angel Biotechnology is in the pharmaceuticals & biotechnology sector and is currently trading at 0.29p per share. In the last year Angel Biotechnology's share price has ranged from 0.075p to 0.65p.

Antisoma (LSE: ASM) is a biotechnology company specialising in the development of novel drugs for the treatment of cancer. Antisoma is in the pharmaceuticals & biotechnology sector and is currently trading at 30.75p per share. In the last year Antisoma's share price has ranged from 22.00p to 37.75p and brokers are currently rating this stock as 'strong buy'.

AorTech International (AIM:
AOR), along with its subsidiaries, is engaged in the development of biomaterials. The Company develops and manufactures biostable, implantable polymers, including Elast-Eon, the biostable implantable silicone-urethane copolymer. Elast-Eon is used in cardiology, orthopedic, urological and gastroenterological applications, including pacing leads, cardiac cannulae and stents. Aortech International is in the health care equipment & services sector and is currently trading at 160.00p per share. In the last year Aortech International's share price has ranged from 130.00p to 190.00p.

Aqua Bounty Technologies (AIM:
ABTX) develops and markets biotechnology products to enhance the profitability of commercial fish and shrimp farming operations.

Ark Therapeutics (AIM:
AKT) is in the pharmaceuticals & biotechnology sector and is currently trading at 32.50p per share. In the last year Ark Therapeutics's share price has ranged from 32.50p to 57.00p and brokers are currently rating this stock as 'neutral'.

Asterand (LSE: ATD)
is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Their mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success.

Avacta (AIM: AVCT) innovative products and expert services provide solutions to high value problems in detection and analysis of biological materials and chemicals within the pharmaceutical, healthcare, security and industrial sectors. Avacta Group is in the pharmaceuticals & biotechnology sector and is currently trading at 1.80p per share. In the last year Avacta Group's share price has ranged from 1.25p to 2.63p and brokers are currently rating this stock as 'strong buy'.


Axis-Shield (LSE:
ASD) is focused on the development and manufacturing of in vitro diagnostic tests for use in clinical laboratories and at the point of care. In the laboratory sector Axis-Shield specialises in proprietary markers for diagnosis and management of critical illnesses such as cardiovascular and neurodegenerative diseases and rheumatoid arthritis. Axis-Shield is in the pharmaceuticals & biotechnology sector and is currently trading at 408.00p per share. In the last year Axis-Shield's share price has ranged from 282.00p to 452.00p and brokers are currently rating this stock as 'buy'.

BTG (LSE: BGC) is a growing life sciences company focused on the development and commercialisation of pharmaceuticals targeting neurological and other disorders. BTG is a specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists.

Cobra Bio-Manufacturing (AIM:
CBF) manufacture both DNA and protein based pharmaceuticals for clinical trials. Cobra Bio-Manufacturing is in the pharmaceuticals & biotechnology sector and is currently trading at 3.88p per share. In the last year Cobra Bio-Manufacturing's share price has ranged from 1.00p to 4.13p.

e-Therapeutics (AIM:
ETX) is a drug discovery company. It has proprietary systems biology technology which it uses to discover potential new treatments for diseases for which either there are no existing treatments or current treatments are unsatisfactory. e-Therapeutics is in the pharmaceuticals & biotechnology sector and is currently trading at 42.00p per share. In the last year e-Therapeutics's share price has ranged from 28.50p to 43.50p.

Fusion IP (AIM: FIP)
owns the rights to 100% of the university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to invest in some the world's most advanced and exciting science, turning world class research into business through the creation of a growing portfolio of companies, in fields as varied as drug discovery, alternative energy and engineering.

Genus (LSE: GNS) creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Genus applies science to animal breeding. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors. It is a provider of bovine genetics and reproduction services, marketing in more than 70 countries.

Helius Energy (AIM: HEGY)
is a United Kingdom-based company engaged in installing and operating biomass-fired renewable electricity generation plants. Helius Energy is in the electricity sector and is currently trading at 26.00p per share. In the last year Helius Energy's share price has ranged from 16.00p to 34.50p.

ImmuPharma (AIM:
IMM) is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies.  Immupharma is in the pharmaceuticals & biotechnology sector and is currently trading at 99.00p per share. In the last year Immupharma's share price has ranged from 54.50p to 136.00p and brokers are currently rating this stock as 'strong buy'.

Intercytex (AIM: ICX) is the leading developer of regenerative medicine products to restore skin and hair. Intercytex uses its fully integrated cell technology platform to develop living, human cell-based products that harness the innate ability of human cells to regenerate and repair the body, at commercially viable scale in attractive markets.

Kiotech Intl (AIM:
KIO) is a biotechnology company working in partnership with the UK Government agency Cefas (Centre for Environment, Fisheries & Aquaculture Science). Kiotech is a UK based company, specialising in the on going development of Biochemical attractants for use in the Global sports fishing, commercial fishing and Aquaculture markets.

Medgenics (AIM: MEDG) is the US incorporated holding company of a biopharmaceutical group. The Group's research & development and administrative operations are conducted by Medgenics Medical (Israel) Limited the Company's wholly owned subsidiary from premises. Medgenics is in the pharmaceuticals & biotechnology sector and is currently trading at 8.25p per share. In the last year Medgenics's share price has ranged from 2.75p to 10.75p.

Nanoco Group (LSE: NANO) partners major R&D and blue-chip industrial organisations in the development of applications incorporating semiconductor nanoparticles, “quantum dots”. Nanoco is in the technology hardware & equipment sector and is currently trading at 69.00p per share. In the last year Nanoco Group's share price has ranged from 21.00p to 78.00p and brokers are currently rating this stock as 'strong buy'.

NextGen Group (AIM:
NGG) is engaged in research and development services, and manufacture and sale of products and technology for use within the protein research industry. NextGen Group is in the pharmaceuticals & biotechnology sector and is currently trading at 0.11p per share. In the last year NextGen Group's share price has ranged from 0.085p to 0.16p.

Ondine Bio (AIM/TSX: OBP) develops non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products using PhotoDynamic Disinfection technology.

Phytopharm (LSE: PYM) is a United Kingdom-based pharmaceutical development and functional food company. Its products are developed from medicinal plants. Phytopharm is in the pharmaceuticals & biotechnology sector and is currently trading at 16.50p per share. In the last year Phytopharm's share price has ranged from 3.25p to 26.75p and brokers are currently rating this stock as 'strong buy'.

Proteome Sciences (AIM: PRM) is engaged in the research and development, primarily in the field of proteomics, using techniques to detect and characterize proteins in diseases for diagnostic, prognostic and therapeutic applications. Proteome Sciences is in the pharmaceuticals & biotechnology sector and is currently trading at 27.00p per share. In the last year Proteome Sciences's share price has ranged from 20.25p to 34.50p and brokers are currently rating this stock as 'strong buy'.

Proximagen Neuroscience (AIM:
PRX) has developed a broad pipeline of partnered and unpartnered drug candidate programmes to address the significant unmet medical needs of patients with neurodegenerative disease. Proximagen Neuroscience is in the pharmaceuticals & biotechnology sector and is currently trading at 110.00p per share. In the last year Proximagen Neuroscience's share price has ranged from 108.50p to 155.00p.

ReGen Therapeutics (AIM:
RGT) is principally engaged in the drug development and ancillary services, and conducting pharmacokinetic and pharmacodynamic research. ReGen Therapeutics is in the pharmaceuticals & biotechnology sector and is currently trading at 3.25p per share. In the last year ReGen Therapeutics's share price has ranged from 3.13p to 7.50p.

Reliance GeneMedix (AIM: GMX), formerly GeneMedix plc, is a United Kingdom-based biopharmaceutical company engaged in the development and manufacture of biopharmaceuticals, including biosimilars, which are a generic version of therapeutic proteins. Reliance GeneMedix plc is in the pharmaceuticals & biotechnology sector and is currently trading at 1.25p per share. In the last year Reliance GeneMedix plc's share price has ranged from 1.25p to 1.75p.

ReNeuron (AIM: RENE) is a UK-based adult stem cell company whose primary objective is the development of stem cell therapies. ReNeuron is in the pharmaceuticals & biotechnology sector and is currently trading at 6.30p per share. In the last year ReNeuron's share price has ranged from 2.75p to 14.75p and brokers are currently rating this stock as 'strong buy'.

Renovo (LSE: RNVO)
is a biopharmaceutical product company and is a leader in the discovery and development of drugs to improve the appearance of scars and enhance wound healing. Renovo Group is in the pharmaceuticals & biotechnology sector and is currently trading at 25.25p per share. In the last year Renovo Group's share price has ranged from 18.00p to 33.00p and brokers are currently rating this stock as 'neutral'.

Silence Therapeutics (AIM: SLN)
, formerly SR Pharma plc, is engaged in the research and development of pharmaceutical products.

Source BioScience (AIM:
SBS) is in the pharmaceuticals & biotechnology sector and is currently trading at 8.00p per share. In the last year Source BioScience's share price has ranged from 4.38p to 9.25p and brokers are currently rating this stock as 'buy'.

Valirx (AIM: VAL) is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. ValiRx is in the pharmaceuticals & biotechnology sector and is currently trading at 2.13p per share. In the last year ValiRx's share price has ranged from 1.50p to 5.00p.

Vernalis (LSE:
VER) is a specialty bio-pharmaceutical company primarily focused on drugs for the treatment of central nervous system (NYSE:CNS) disorders. Vernalis is in the pharmaceuticals & biotechnology sector and is currently trading at 82.00p per share. In the last year Vernalis's share price has ranged from 43.55p to 105.00p and brokers are currently rating this stock as 'buy'.


Verona Pharma (AIM:
VRP) is involved in drug discovery focused on the discovery and development of new therapeutic drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory and inflammatory diseases. Verona Pharma is in the pharmaceuticals & biotechnology sector and is currently trading at 15.50p per share. In the last year Verona Pharma's share price has ranged from 2.25p to 19.00p and brokers are currently rating this stock as 'strong buy'.

AGI Therapeutics (AIM: AGI) is a speciality pharmaceutical company focused on the development and commercialization of differentiated drug product candidates for gastrointestinal diseases and disorders.


Allergy Therapeutic (AIM: AGY) is a fully integrated specialty pharmaceuticals business currently focused upon the treatment and prevention of allergies.  Allergy Therapeutics is in the pharmaceuticals & biotechnology sector and is currently trading at 15.00p per share. In the last year Allergy Therapeutics' share price has ranged from 6.50p to 21.75p and brokers are currently rating this stock as 'neutral'.

Alliance Pharma (AIM:
APH) is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K. . Alliance Pharma is in the pharmaceuticals & biotechnology sector and is currently trading at 22.75p per share. In the last year Alliance Pharma's share price has ranged from 2.63p to 23.50p and brokers are currently rating this stock as 'strong buy'.

Ardana Bioscience (LSE:
ARA) is a pharmaceutical company specialising in the field of reproductive health.

Astrazeneca (LSE: AZN) is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 employees and operates in over 100 countries with growing presence in important emerging markets.

Beximco Pharma (AIM:
BXP) manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients, and large volume intravenous fluids to local and international markets.

China Medical (AIM: CMSH) is an intergraded and profitable pharmaceutical company, which develops, manufactures, sells and markets prescription drugs and medical devices in China. China Medical System Holdings is in the pharmaceuticals & biotechnology sector and is currently trading at 378.50p per share. In the last year China Medical System Holdings's share price has ranged from 105.50p to 433.50p and brokers are currently rating this stock as 'strong buy'.

Cyprotex (AIM: CRX) does drug discovery and industrial scale testing for pharmaceutical companies. Cyprotex is in the pharmaceuticals & biotechnology sector and is currently trading at 3.50p per share. In the last year Cyprotex's share price has ranged from 2.00p to 6.25p.

Dechra Pharm (LSE: DPH) comprises six businesses operating under two Divisions, Pharmaceuticals and Services. Both divisions are focused on the veterinary market with a key area of specialisation being on companion animal products.

Eco Animal (AIM: EAH)
manufactures and supplies specialty chemicals, animal feed and animal health products. ECO Animal Health Group is in the pharmaceuticals & biotechnology sector and is currently trading at 182.50p per share. In the last year ECO Animal Health Group's share price has ranged from 125.00p to 212.50p.

Fulcrum Pharma (AIM: FUL) is a drug development and regulatory services business that provides its customers with resources to achieve drug development and regulatory approval milestones. Fulcrum is in the pharmaceuticals & biotechnology sector and is currently trading at 3.63p per share. In the last year Fulcrum's share price has ranged from 2.00p to 4.00p and brokers are currently rating this stock as 'neutral'.

Futura Medical (AIM: FUM)
is a United Kingdom-based company engaged in the research and development of pharmaceutical drugs and medical devices and their commercial exploitation. The Company is focuses on developing a portfolio of products in sexual healthcare and pain relief management. Futura Medical is in the pharmaceuticals & biotechnology sector and is currently trading at 32.25p per share. In the last year Futura Medical's share price has ranged from 20.75p to 43.50p and brokers are currently rating this stock as 'buy'.

GlaxoSmithKline (LSE: GSK) supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions. GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.

Goldshield Group (LSE: GSD) is engaged in the in the development, marketing and distribution of pharmaceutical and healthcare products. It operates in five business units: Retail Brands, Retail Generics, Hospitals, Consumer Health Europe (CH E) and, Consumer Health North America (CH NA). In the last year Goldshield Group's share price has ranged from 182.75p to 505.00p and brokers are currently rating this stock as 'strong buy'.

GW Pharm (AIM: GWP)
is in the pharmaceuticals & biotechnology sector and is currently trading at 93.00p per share. In the last year GW Pharmaceuticals' share price has ranged from 27.50p to 101.50p and brokers are currently rating this stock as 'strong buy'.

Henderson Morley (AIM: HML)
is engaged in the development of drugs and vaccines for the pharmaceutical industry. The Company has a pipeline of clinical and pre-clinical candidates in a range of disease areas, including skin warts; verrucae (warts on the feet and toes); herpes simplex infections of the mouth and genitalia, and eyes; adenovirus infection of the eyes, and recurrent respiratory papillomatosis (RRP). Henderson Morley is in the pharmaceuticals & biotechnology sector and is currently trading at 0.39p per share. In the last year Henderson Morley's share price has ranged from 0.25p to 0.70p.

Hikma Pharmaceuticals (LSE: HIK) is focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.

IS Pharma (NASDAQ:ISPH) is in the pharmaceuticals & biotechnology sector and is currently trading at 90.50p per share. In the last year IS Pharma's share price has ranged from 56.50p to 97.50p and brokers are currently rating this stock as 'strong buy'.

Lipoxen (AIM: LPX) is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms from which it has already progressed two products into clinical development. . Lipoxen is in the pharmaceuticals & biotechnology sector and is currently trading at 13.00p per share. In the last year Lipoxen's share price has ranged from 4.75p to 21.75p.


Medical Marketing (AIM:
MMG) is a United Kingdom-based pharmaceutical development company. The Company identifies and acquires, from technologies for the treatment of cancer. It also offers a limited range of technical support services to United Kingdom academic and commercial bodies, which generates revenue and provides access to potential in-licensing opportunities.

Minster Pharma (AIM: MPM) is a drug development company focused on the treatment of neurological and psychiatric conditions. Minster Pharmaceuticals is in the pharmaceuticals & biotechnology sector and is currently trading at 5.13p per share. In the last year Minster Pharmaceuticals' share price has ranged from 3.75p to 24.50p.

Neuropharm (AIM: NPH)
is a speciality pharmaceutical group focused on the development of drugs for the treatment and management of selected developmental and degenerative disorders. Neuropharm Group is in the pharmaceuticals & biotechnology sector and is currently trading at 15.50p per share. In the last year Neuropharm Group's share price has ranged from 5.38p to 119.00p and brokers are currently rating this stock as 'neutral'.

Oxford Biomed (AIM: OXB)
is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. Oxford Biomedica is currently trading at 12.00p per share. In the last year Oxford Biomedica's share price has ranged from 5.88p to 17.00p and brokers are currently rating this stock as 'buy'.

Plethora (AIM: PLE)
is focused on the development and marketing of products for the treatment of urological disorders. Plethora Solutions Holdings is in the pharmaceuticals & biotechnology sector and is currently trading at 15.50p per share. In the last year Plethora Solutions Holdings' share price has ranged from 14.50p to 33.50p.

ProStrakan (LSE: PSK) is focused on the development and  commercialisation of prescription medicines for the treatment of unmet  therapeutic needs. ProStrakan is in the pharmaceuticals & biotechnology sector and is currently trading at 95.00p per share. In the last year ProStrakan's share price has ranged from 56.00p to 155.00p and brokers are currently rating this stock as 'buy'.

Ransom (William) (AIM: RNSM)
is a United Kingdom-based company engaged in the supply of branded medicines, vitamins and food supplements, the manufacture of pharmaceutical products, and the extraction of plant material for the healthcare, food and beverage industries. Ransom(William) & Son is in the pharmaceuticals & biotechnology sector and is currently trading at 4.75p per share. In the last year Ransom(William) & Son's share price has ranged from 4.13p to 8.25p.

Sareum Holdings (AIM: SAR) is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. It focuses on cancer drug discovery programmes. Sareum is in the pharmaceuticals & biotechnology sector and is currently trading at 0.47p per share. In the last year Sareum's share price has ranged from 0.055p to 0.59p.


Shire (LSE: SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (NYSE:HGT), gastrointestinal (NYSE:GI) and renal diseases.


Sinclair Pharma (AIM: SPH) has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. For more in depth information please click here. Sinclair Pharma is in the pharmaceuticals & biotechnology sector and is currently trading at 34.75p per share. In the last year Sinclair Pharma's share price has ranged from 13.25p to 47.00p and brokers are currently rating this stock as 'neutral'.

Skyepharma (LSE:
SKP) is a specialist drug delivery company developing oral and inhalation products.  With a wide range of patented and proven technologies, SkyePharma aims to make good drugs better.

Summit Corp (AIM: SUMM) is a drug discovery business with extensive expertise in the use and understanding of chemical genomics and its application to human disease. Summit Corporation is in the pharmaceuticals & biotechnology sector and is currently trading at 6.75p per share. In the last year Summit Corporation's share price has ranged from 1.13p to 28.00p and brokers are currently rating this stock as 'strong buy'.

Synairgen (AIM: SNG) is the holding company for Synairgen Research Limited, a drug discovery and development company focused on developing therapies which address the causes, rather than the symptoms, of respiratory disease. Synairgen is in the pharmaceuticals & biotechnology sector and is currently trading at 34.75p per share. In the last year Synairgen's share price has ranged from 13.00p to 58.00p.

Syntopix Group (AIM:
SYN) is a drug discovery and development company engaged in the discovery and development of drugs for the topical treatment of dermatological diseases. The Company is focused on acne and staphylococcus aureus infections. Syntopix is in the pharmaceuticals & biotechnology sector and is currently trading at 76.00p per share. In the last year Syntopix's share price has ranged from 68.50p to 82.50p.

Taihua (AIM: TAIH)
are principally involved in the development of active pharmaceutical ingredients namely paclitaxel and homoharringtonine predominantly for use in the treatment of cancer. Taihua is in the pharmaceuticals & biotechnology sector and is currently trading at 12.25p per share. In the last year Taihua's share price has ranged from 4.25p to 15.50p and brokers are currently rating this stock as 'neutral'.

Vectura (AIM:
VEC) is principally engaged in the research and development of therapeutic products and drug delivery systems for human use. The Company is focused on the development of inhaled pharmaceuticals.

www.proactiveinvestors.co.uk/companies/news/12174/renovo-fusion-ip-and-bioneutral-confirmed-for-20-january-investor-forum-12174.html



Disclosure: The author holds no positions in the company